Research Article
Real-World Efficacy and Safety of Tafluprost in Primary Open-Angle Glaucoma Patients with Corneal Disorders: A Taiwan Experience
Table 1
Demographics and baseline characteristics of enrolled patients.
| Variable | Results (N = 17) |
| Sex (n, %) | Male | 11 (64.7%) | Female | 6 (35.3%) |
| Age (mean ± SD; years) | 62.2 ± 10.6 |
| Diagnosis, right eye (n, %) | POAG | 17 (100.0%) | OH | 0 | Others | 0 | Duration of diagnosis (mean ± SD; months) | 48.8 ± 37.6 |
| Diagnosis, left eye (n, %) | POAG | 16 (94.0%) | OH | 0 | Others | 1 (6.0%) | Duration of diagnosis (mean ± SD; months) | 45.9 ± 36.9 |
| Study eye (n, %) | Right | 9 (53.0%) | Left | 8 (47.0%) |
| Concomitant ocular medications (n, %) | Sulfamethoxazole | 10 (58.8%) | Pirenoxine | 8 (47%) | Cyanocobalamin | 4 (23.5%) | Neostigmine | 3 (17.6%) |
|
|
OH, ocular hypertension; POAG, primary open-angle glaucoma; SD, standard deviation.
|